MXPA05009098A - Crystalline non-solvated 1- (4-(2- piperidinylethoxy) phenoxy)- 2-(4 -methanesulfonylphenyl) -6- hydroxynaphthalene hydrochloride. - Google Patents

Crystalline non-solvated 1- (4-(2- piperidinylethoxy) phenoxy)- 2-(4 -methanesulfonylphenyl) -6- hydroxynaphthalene hydrochloride.

Info

Publication number
MXPA05009098A
MXPA05009098A MXPA05009098A MXPA05009098A MXPA05009098A MX PA05009098 A MXPA05009098 A MX PA05009098A MX PA05009098 A MXPA05009098 A MX PA05009098A MX PA05009098 A MXPA05009098 A MX PA05009098A MX PA05009098 A MXPA05009098 A MX PA05009098A
Authority
MX
Mexico
Prior art keywords
piperidinylethoxy
methanesulfonylphenyl
solvated
phenoxy
crystalline non
Prior art date
Application number
MXPA05009098A
Other languages
Spanish (es)
Inventor
Michael Remick David
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/003349 external-priority patent/WO2004009086A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA05009098A publication Critical patent/MXPA05009098A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to crystalline non-solvated 1- (4-2- piperidinylethoxy) phenoxy)-2- (4-methanesulfonylphenyl) -6- hydroxynaphthalene hydrochloride, useful as a selective estrogen receptor modulator.
MXPA05009098A 2003-02-25 2004-01-21 Crystalline non-solvated 1- (4-(2- piperidinylethoxy) phenoxy)- 2-(4 -methanesulfonylphenyl) -6- hydroxynaphthalene hydrochloride. MXPA05009098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45023303P 2003-02-25 2003-02-25
PCT/IB2003/003349 WO2004009086A1 (en) 2002-07-22 2003-07-16 Selective estrogen receptor modulators containing a phenylsulfonyl group
PCT/US2004/000020 WO2004075894A1 (en) 2003-02-25 2004-01-21 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride

Publications (1)

Publication Number Publication Date
MXPA05009098A true MXPA05009098A (en) 2005-11-17

Family

ID=32929435

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009098A MXPA05009098A (en) 2003-02-25 2004-01-21 Crystalline non-solvated 1- (4-(2- piperidinylethoxy) phenoxy)- 2-(4 -methanesulfonylphenyl) -6- hydroxynaphthalene hydrochloride.

Country Status (8)

Country Link
EP (1) EP1601356A1 (en)
AU (1) AU2004216258B2 (en)
BR (1) BRPI0407690A (en)
CA (1) CA2512663A1 (en)
HR (1) HRP20050675A2 (en)
MX (1) MXPA05009098A (en)
NO (1) NO20054400L (en)
WO (1) WO2004075894A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713770A1 (en) * 2004-01-29 2006-10-25 Eli Lilly And Company Selective estrogen receptor modulators
SI1928409T1 (en) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (en) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Iron with actively cooled soleplate and method for cooling the soleplate.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484798A (en) 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US6703407B1 (en) 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US5929090A (en) 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
JP4656939B2 (en) * 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー Selective estrogen receptor modulators containing phenylsulfonyl groups

Also Published As

Publication number Publication date
AU2004216258B2 (en) 2006-10-19
EP1601356A1 (en) 2005-12-07
HRP20050675A2 (en) 2005-10-31
CA2512663A1 (en) 2004-09-10
AU2004216258A1 (en) 2004-09-10
WO2004075894A1 (en) 2004-09-10
NO20054400L (en) 2005-09-22
BRPI0407690A (en) 2006-03-01

Similar Documents

Publication Publication Date Title
GB2436248B (en) A system and associated methods for network aware dynamic power management
AU2002352633A1 (en) Piperidine compounds for use as orexin receptor antagonist
HK1071572A1 (en) PyrazoloÄ1,5-AÜpyrimidine compounds as cyclin dependent kinase inhibitors
AP2005003264A0 (en) Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
CR7962A (en) 1- (4- (2-Piperidinylethoxy) phenoxy) -2 - (- 4 Methanesulfoniphenyl) -6-crystalline hydroxynaphthalene hydrochloride
TW200510347A (en) Process for organic compounds
TW200513256A (en) Antifungal and/or antimycotic external preparation for nail
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2002335519A1 (en) Sulfur free cutting steel for machine structural use
NO20054400L (en) Crystalline unsolvated 1- (4- (2-piperidinylethoxy) phenoxy) -2- (4-methanesulfonylphenyl) -6-hydroxynaphthalene hydrochloride
TW200618799A (en) Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof
AU2003290469A1 (en) Cutting machine for organic plant materials, especially for tobacco
ITTO20020131U1 (en) ,, CARDBOARD SHEET BENDING-BENDING MACHINE ,,
EA200501339A1 (en) CRYSTALLINE NESOLVATED HYDROCHLORIDE 1- (4- (2- PIPERIDINYLETOXY) PHENOXY) -2- (4-METHESULFONYLPHENYL) -6-HYDROXYNAPHTHALINE
HK1055059A2 (en) 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
WO2006010079A3 (en) Process for preparing naratriptan hydrochloride
AU2003252653A1 (en) Nailing machine
AU2003230309A1 (en) As a pkc inhibitor, inhibitor for angiogenesis containing 6-anilinoquinoline-5,8-quinone as an effective ingredient
GB0515028D0 (en) Management system for business investment
AU2003230738A1 (en) Active-loop, spatially-combined amplifier
TW537133U (en) Improvement for hammering type binding machine
AU2003206240A1 (en) A clip for newspaper
ZA200308265B (en) Imidazoline compounds, a process for their preparation and pharmaceutical compositions containing them.
EP1391274A1 (en) Package for tool sets
HK1057368A1 (en) New indoline compounds, a process for their preparation and pharmaceutical compositions containing them.